ClinicalTrials.gg

Program

HS-20122

A development code. Also written as “HS-20122+Aumolertinib”, “HS-20122+Adbrelimab” and “HS-20122+Adbrelimab+Platinum-based Chemo”.

In Hansoh Pharmaceutical Group's pipeline, EGFR/c-MET bispecific ADC. Its studies are mostly in Lung Neoplasms, led by Hansoh Pharmaceutical Group.

Furthest: phase 1, since Apr 7, 20252 company-led studies, 2 open or runningNext primary completion: Jan 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group22 open or runningphase 1since Apr 7, 2025Apr 7, 2025Jan 31, 2028phase 1 · NCT06927570
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20122 (EGFR/c-MET bispecific ADC), phase 1, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06927570 · 1,050 planned · China
  2. Jun 8, 2026Phase 1 study in Lung NeoplasmsNCT07645222 · 396 planned · China

Ahead

  1. Jan 31, 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT06927570
  2. Oct 31, 2028Primary completion: phase 1 study in Lung NeoplasmsNCT07645222

TargetBeta

“EGFR/c-MET bispecific ADC”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07645222Lung Neoplasms · China1RecruitingOct 31, 2028396
NCT06927570Advanced Solid Tumors · China1RecruitingJan 31, 20281,050

How it is read

Names in the registry

  • “HS-20122+Aumolertinib”, 1 entry
  • “HS-20122+Adbrelimab”, 1 entry
  • “HS-20122+Adbrelimab+Platinum-based Chemo”, 1 entry
  • “HS-20122”, 1 entry

Codes read as this program: HS20122.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.